<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04916509</url>
  </required_header>
  <id_info>
    <org_study_id>A5481136</org_study_id>
    <secondary_id>TREASURE</secondary_id>
    <nct_id>NCT04916509</nct_id>
  </id_info>
  <brief_title>Treatment Patterns and Clinical Outcomes Among Patients Receiving Palbociclib Combinations for Hormone Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2 ) Advanced/Metastatic Breast Cancer in the Arabian Gulf Region</brief_title>
  <official_title>Treatment Patterns and Clinical Outcomes Among Patients Receiving Palbociclib Combinations for Hormone Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Advanced/Metastatic Breast Cancer in the Arabian Gulf Region Like Saudi Arabia, UAE and Other GCC Countries: A Retrospective Study (Treasure Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <brief_summary>
    <textblock>
      retrospective non-interventional study (NIS) that aims to describe the demographics, clinical&#xD;
      characteristics, clinical outcomes, and treatment patterns, among patients receiving&#xD;
      palbociclib for the treatment of HR+/HER2- metastatic/locally advanced breast cancer (BC)&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 31, 2021</start_date>
  <completion_date type="Anticipated">October 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Demographical Characteristics of Participants</measure>
    <time_frame>Upon BC diagnosis up to date of index treatment (from data collected and observed retrospectively between 01 January 2015 and 01 March 2019)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Demographical Characteristics of Participants: Biomarker status</measure>
    <time_frame>Upon BC diagnosis up to date of index treatment (from data collected and observed retrospectively between 01 January 2015 and 01 March 2019)</time_frame>
    <description>Biomarker status - (estrogen receptor [ER], progesterone receptor [PR], HER-2 neu, Ki67, Germline BRCA [gBRCA] testing).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Characteristics of Participants: Description of diagnosis</measure>
    <time_frame>Upon BC diagnosis up to date of index treatment (from data collected and observed retrospectively between 01 January 2015 and 01 March 2019)</time_frame>
    <description>Description of diagnosis - staging, node status, menopause status, diagnosis for which palbociclib combination was prescribed, sites of metastases, de novo vs. recurrent disease.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients receiving adjuvant therapies</measure>
    <time_frame>Upon diagnosis of BC (from data collected and observed retrospectively between 01 January 2015 and 01 March 2019)</time_frame>
    <description>Adjuvant therapies received for the treatment of early or locally advanced breast cancer (Stages 0-IIIa) (if available)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants receiving treatment for advanced/metastatic BC before and after palbociclib combination use</measure>
    <time_frame>Upon diagnosis of metastatic/locally advanced HR+/HER2 BC for a maximum of 4 years approximately (from data collected and observed retrospectively between 01 January 2015 and 01 March 2019)</time_frame>
    <description>Treatments and supportive therapies received since metastatic/locally advanced HR+/HER2- diagnosis. Duration of treatments. Reasons for regimen changes. Starting dose, duration of treatment, changes in dose, interruptions, cycle delays and discontinuations. Where possible reasons for change in treatment. Line of treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with dose changes associated with palbociclib use</measure>
    <time_frame>From 01 January 2015 to 30 September 2019</time_frame>
    <description>Starting dose, duration of treatment, changes in dose, interruptions, cycle delays and discontinuations. Where possible, reasons for change in treatment. Line of treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants to discontinue treatment associated with palbociclib use</measure>
    <time_frame>From 01 January 2015 to 30 September 2019</time_frame>
    <description>Starting dose, duration of treatment, changes in dose, interruptions, cycle delays and discontinuations. Where possible, reasons for change in treatment. Line of treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participant receiving supportive therapies while receiving palbociclib combination treatment</measure>
    <time_frame>From 01 January 2015 to 30 September 2019</time_frame>
    <description>Supportive therapies received since metastatic/locally advanced HR+/HER2- diagnosis while receiving palbociclib combination treatments. Duration of treatments.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of patients who are progression free at multiple intervals</measure>
    <time_frame>From date of index treatment to date of disease progression, date of death, or end of study whichever came first, assessed up to 57 months</time_frame>
    <description>Proportion of progression free survival/time to progression (at intervals per standard of care) (eg. 12, 18 months).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>From date of index treatment up to 57 months</time_frame>
    <description>Proportion of objective response rate (at intervals per standard of care).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of patients alive 1 and 2 years post palbociclib combination initiation depending on availability of follow-up data (if available)</measure>
    <time_frame>From 01 January 2015 to 30 September 2019</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">665</enrollment>
  <condition>Breast Neoplasms</condition>
  <arm_group>
    <arm_group_label>Palbociclib plus an aromatase inhibitor</arm_group_label>
    <description>Adult metastatic breast cancer patients who initiated Palbociclib + an aromatase inhibitor.&#xD;
Data will be retrospectively abstracted over an observational look-back period from 01st January 2015 to 30th September 2019.&#xD;
Aligned with Locally Approved Indication</description>
  </arm_group>
  <arm_group>
    <arm_group_label>palbociclib plus fulvestrant</arm_group_label>
    <description>Adult metastatic breast cancer patients who initiated Palbociclib + fulvestrant. Data will be retrospectively abstracted over an observational look-back period from 01st January 2015 to 30th September 2019.&#xD;
Aligned with Locally Approved Indication</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Palbociclib plus an aromatase inhibitor</intervention_name>
    <description>Palbociclib plus an aromatase inhibitor therapy</description>
    <arm_group_label>Palbociclib plus an aromatase inhibitor</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Palbociclib plus fulvestrant</intervention_name>
    <description>Palbociclib plus fulvestrant</description>
    <arm_group_label>palbociclib plus fulvestrant</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Data will be abstracted from the medical records of all eligible patients across 17 - 35&#xD;
        selected sites from Arabian Gulf Region countries. The observational period for patients is&#xD;
        the 57 month-period prior to the study index date. During this period, patients who&#xD;
        initiated treatment with palbociclib between 01st January 2015 and 01st March 2019 will be&#xD;
        considered eligible for participation in the study. Sites from diverse health care settings&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age â‰¥18 years old.&#xD;
&#xD;
          2. HR+/HER2- BC diagnosis with confirmed metastatic/locally advanced disease.&#xD;
&#xD;
          3. Patient initiated on palbociclib (regardless the line of therapy) within the period&#xD;
             between 01st January 2015 and 01st March 2019.&#xD;
&#xD;
          4. Minimum of six months of follow up data since palbociclib initiation.&#xD;
&#xD;
          5. Received palbociclib plus aromatase inhibitor or palbociclib plus fulvestrant in line&#xD;
             with the licensed indication(s).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Prior or current enrolment in an interventional clinical trial for metastatic/locally&#xD;
             advanced BC.&#xD;
&#xD;
          2. Patients who were initiated on palbociclib after 01st March 2019.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Meteb Al-Foheidi</last_name>
    <role>Principal Investigator</role>
    <affiliation>King Abdul-Aziz Medical City, National Guard Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <phone>1-800-718-1021</phone>
    <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hamad Medical Corporation</name>
      <address>
        <city>Doha</city>
        <country>Qatar</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>International Medical Centre</name>
      <address>
        <city>Jeddah</city>
        <country>Saudi Arabia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Guard Health Affairs Hospital</name>
      <address>
        <city>Jeddah</city>
        <country>Saudi Arabia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Al-Manaa General Hospital</name>
      <address>
        <city>Khobar</city>
        <country>Saudi Arabia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>King Fahad General Hospital</name>
      <address>
        <city>Medina</city>
        <country>Saudi Arabia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>King Khalid University Hospital</name>
      <address>
        <city>Riyadh</city>
        <country>Saudi Arabia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Guard Health Affairs</name>
      <address>
        <city>Riyadh</city>
        <country>Saudi Arabia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prince Sultan Military Medical City</name>
      <address>
        <city>Riyadh</city>
        <country>Saudi Arabia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mediclinic City Hospital</name>
      <address>
        <city>Dubai</city>
        <country>United Arab Emirates</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Qatar</country>
    <country>Saudi Arabia</country>
    <country>United Arab Emirates</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>May 19, 2021</study_first_submitted>
  <study_first_submitted_qc>June 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 7, 2021</study_first_posted>
  <last_update_submitted>June 3, 2021</last_update_submitted>
  <last_update_submitted_qc>June 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Retrospective Studies</keyword>
  <keyword>palbociclib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fulvestrant</mesh_term>
    <mesh_term>Palbociclib</mesh_term>
    <mesh_term>Aromatase Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

